Ergothioneine Clinical Research: Findings from GeneIII’s Human Studies

L-ergothioneine research is moving beyond laboratory mechanisms to examine specific outcomes in people. GeneIII’s human research includes menstrual discomfort, postpartum wellbeing, ovarian reserve, liver and kidney markers, sperm health, and cognition.

Available findings include changes in menstrual pain, quality-of-life scores and selected biological measurements. The studies use different designs, from placebo-controlled trials to exploratory before-and-after investigations. The sections below bring together the participants, protocols and findings, with links to published reports or registration resources. Each result relates to the population and formulation studied; research doses are not serving recommendations for every GeneIII product.

Key Takeaways

• GeneIII’s human research explores specific health needs, including menstrual discomfort, postpartum fatigue and ovarian reserve.
• Available studies report changes in pain scores, quality of life and selected biological markers. The meaning of each result depends on the study population and design.
• The summaries below connect the principal findings with their original sources, making GeneIII’s research easier to explore.

GeneIII Clinical Research at a Glance

Registration records can be searched by entering the complete study number on the ChiCTR English website. Research doses describe study protocols, not product serving recommendations. Results relate to the participants and formulations studied.

1. L-Ergothioneine and Menstrual Discomfort

Menstrual pain can interrupt work, study and everyday activities. GeneIII’s menstrual-health study investigated this concern in women with primary dysmenorrhea.

Study Overview

• Participants: 40 women.
• Design: Randomized, double-blind, placebo-controlled.
• Protocol: 120 mg of L-ergothioneine or placebo daily for three menstrual cycles.
• Research focus: Menstrual pain and related symptoms.

Main Finding

Mean peak menstrual pain scores decreased from 4.80 to 2.32 in the L-ergothioneine group, compared with 4.10 to 3.45 in the placebo group. The preprint reports a statistically significant difference between groups at the third cycle.

The placebo group provides an important comparison: pain scores changed in both groups, while the statistical analysis examined whether their outcomes differed. Following participants across three cycles also allowed researchers to observe repeated menstrual periods rather than relying on a single assessment.

This trial provides preliminary human evidence for L-ergothioneine in menstrual comfort. Its findings warrant further investigation in larger populations. New, severe or worsening menstrual pain should be assessed by a healthcare professional.

Registration: ChiCTR2500112557
Read the menstrual-health study

2. L-Ergothioneine and Ovarian Reserve

Ovarian reserve assessment includes markers associated with the remaining follicle pool. One commonly used marker is anti-Müllerian hormone, or AMH, which is interpreted alongside other clinical information.

GeneIII’s ovarian reserve pilot examined women aged 35–45 with suboptimal ovarian function.

Study Overview

• Participants: 40 enrolled; 36 completed.
• Design: Single-center, open-label, self-controlled pilot.
• Protocol: 120 mg of L-ergothioneine daily for three menstrual cycles.
• Research focus: AMH, other hormonal measurements and related symptoms.

Main Finding

Mean AMH increased from 1.81 to 2.46 ng/mL, approximately 35.9% above baseline. The study was published in BMC Women’s Health on June 17, 2026.

This finding concerns an ovarian reserve marker, not an individual’s likelihood of pregnancy. Pregnancy and live birth were not study endpoints.

The pilot compared participants with their own starting measurements rather than with a placebo group. It therefore documents changes during supplementation and provides a basis for controlled follow-up research; it does not establish that supplementation alone caused those changes.

Registration: ChiCTR2500104484
Read the ovarian reserve study

3. L-Ergothioneine and Postpartum Recovery

Recovery after childbirth can involve fatigue, changes in daily functioning and differences in overall wellbeing. GeneIII’s postpartum study assessed these experiences through separate quality-of-life and fatigue questionnaires.

Study Overview

• Participants: 40 women who had completely stopped breastfeeding.
• Design: Randomized, double-blind, placebo-controlled.
• Protocol: 120 mg of L-ergothioneine or placebo daily for 30 days.
• Research focus: Health-related quality of life and fatigue.

Main Findings

The study summary reports the following changes in the supplementation group at day 30:

These percentages describe changes within the supplementation group, not percentage differences versus placebo. The physical-fatigue subscale is also distinct from the total fatigue score.

Assessing these outcomes separately helps describe different aspects of recovery rather than treating wellbeing as a single measure. The findings apply to the population studied—women who had stopped breastfeeding—and do not establish suitability during breastfeeding.

Registration: ChiCTR2500114171
Read the postpartum-recovery study

4. L-Ergothioneine and Liver Health

Liver-health research often includes enzymes such as alanine aminotransferase and aspartate aminotransferase, commonly abbreviated as ALT and AST. These measurements contribute to liver assessment, with their interpretation depending on the broader clinical context.

GeneIII’s study assessed liver-related measurements alongside questionnaire-based outcomes.

Study Overview

• Participants: 30 adults.
• Design: Open-label, self-controlled.
• Protocol: 60 mg of L-ergothioneine daily for 30 days.
• Research focus: Liver enzymes and PSQI-related measures.

Main Findings

The report describes reductions in liver enzymes relative to baseline. It also reports a 51.56% reduction in the daytime dysfunction component of the Pittsburgh Sleep Quality Index, or PSQI.

The PSQI result refers specifically to daytime functioning associated with sleep difficulties. It is not a 51.56% improvement in overall sleep quality or a direct measurement of energy production.

Because the study compared participants with their own baseline, its findings are exploratory. They identify laboratory and functional outcomes that can be examined further in controlled research.

Registration: ChiCTR2400093739
Read the liver-health study

5. L-Ergothioneine and Kidney Health

Kidney-related research can assess both laboratory measurements and participant-reported symptoms. Examining these separately provides a more detailed picture than a broad statement about “kidney improvement.”

Study Overview

• Participants: 31 adults aged 45–70 enrolled; 27 completed.
• Design: Open-label, self-controlled.
• Protocol: 120 mg of L-ergothioneine daily for 90 days.
• Research focus: Kidney-related laboratory markers and urinary symptoms.

Research Findings

The report describes changes in selected measurements, while other outcomes did not change significantly.

The 90-day observation period adds longer-term measurements to the research presented here. Its exploratory findings help identify which outcomes may be useful to investigate in subsequent controlled trials.

These results do not establish L-ergothioneine as a treatment for kidney disease. Anyone managing an existing kidney condition should discuss supplement use with their treating clinician.

Registration: ChiCTR2500108897
Read the kidney-health study

6. L-Ergothioneine and Sperm Health

Sperm motility and morphology are components of semen analysis used in male reproductive-health assessment. Motility describes movement, while morphology assesses the proportion of sperm with normal form.

GeneIII’s research summary describes a multicenter study examining these measurements in men aged 18–55 with progressive sperm motility below 50%.

Study Overview

• Participants: 32 enrolled; 30 completed.
• Design: Multicenter, open-label, self-controlled.
• Protocol: 120 mg of L-ergothioneine daily for 90 days.
• Assessments: Baseline, day 45 and day 90.
• Source: GeneIII research summary, version 1.0, dated April 24, 2026.

Main Findings

The summary reports the following changes between baseline and day 90:

These results describe changes within the study group, not differences versus placebo. The research used participants’ own baseline measurements as the comparison and did not establish improvements in pregnancy or live-birth rates.

The findings extend GeneIII’s research into male reproductive-health measurements and provide an exploratory basis for further controlled investigation.

Registration: ChiCTR2500111625. Search the registration number on the ChiCTR English website.

For the research summary and available supporting information, contact GeneIII.

7. L-Ergothioneine and Cognitive Function

Cognitive research examines functions such as memory and attention using defined assessments. Findings depend on the participants and tests involved; results in one population cannot automatically be applied to everyone seeking cognitive support.

GeneIII has registered a study involving adults with mild cognitive impairment.

• Research focus: Cognitive function in a defined clinical population.
• Registration: ChiCTR2500112606.
• Information presented here: Registered research direction; no efficacy findings are reported in this article.

For protocol information and the latest recorded status, search ChiCTR2500112606 on the ChiCTR English website.

Understanding the Findings

GeneIII’s studies measure different aspects of health. A reduction in pain, a change in a laboratory marker and an improvement in a questionnaire score are not interchangeable outcomes.

Study design provides additional context. Placebo-controlled trials compare groups, while self-controlled studies compare participants with their own baseline. Both can contribute information, but a before-and-after change alone does not establish its cause.

The ovarian reserve study is available as a peer-reviewed publication. The linked menstrual, postpartum, liver and kidney reports are preprints. Larger controlled studies and longer follow-up would help clarify the consistency and durability of their findings.

For more about the scientific collaborations and milestones behind GeneIII’s research program, explore Advancing Ergothioneine Research: Scientific Collaborations and Milestones.

From Clinical Research to Daily Use

The GeneIII® L-Ergothioneine 30 mg product provides 30 mg of L-ergothioneine per capsule. The studies described above use protocol-specific formulations, doses and durations to address different research questions. For everyday use, refer to the ingredient information and directions on the specific GeneIII product you choose.

For everyday use:

• Follow the product label rather than adopting a study dose.
• Do not interpret a study’s observation period as a guaranteed time to results.
• Consider whether the study population and outcome relate to your circumstances.
• Seek professional advice when taking medication or managing a health condition.

Human research and quality testing serve complementary purposes. Clinical studies investigate health-related outcomes; quality documentation addresses the ingredient and tested product samples.

View GeneIII L-Ergothioneine product details and directions

Learn about GeneIII purity, capsule content and safety testing

Frequently Asked Questions

Q1: Which GeneIII Studies Used a Placebo Group?

The menstrual-comfort and postpartum-recovery studies used randomized, double-blind, placebo-controlled designs. Their reports may include both changes within each group and comparisons between groups.

Q2: Does a Change in a Research Marker Mean I Will Notice a Benefit?

Not necessarily. Laboratory markers, symptom scores and everyday experiences measure different things. A study describes findings in a particular population under defined conditions; it does not predict an individual response.

Q3: Should I Take the Dose Used in a Clinical Study?

Follow the GeneIII product label. Research doses belong to individual study protocols and are not personalized recommendations. A qualified healthcare professional can advise on your circumstances.

Q4: Where Can I Read the Original Studies?

The relevant papers and preprints are linked within each research section. For registration details, visit the ChiCTR English website and search the complete registration number listed below.

Q5: Do These Studies Apply to Every GeneIII Product?

Each study evaluates a particular formulation, dose and participant group. To understand its relevance to a specific GeneIII product, compare the studied formulation with that product’s ingredient information. Follow the directions on the product label for daily use.

Clinical Trial Registration Reference

Explore Clinical Trial Registrations

Research Update

This article summarizes selected GeneIII-related human studies based on research materials available as of October 2026. It is not an exhaustive list of GeneIII’s research activities. Study status, publication versions and available findings may change as further information becomes available.

Disclaimer

This content is for informational purposes only and does not constitute medical advice. The studies discussed use different designs, including randomized, placebo-controlled trials and open-label, self-controlled studies. Findings should be interpreted in the context of each study’s participants, methods, and publication status. If you are pregnant, breastfeeding, planning pregnancy, taking medication, or managing a medical condition, consult a qualified healthcare professional before use.